biosyn and Axon Neuroscience strengthen their collaboration by establishing a joint venture

Vaccine against fading minds – coupling peptides to a KLH carrier to find and fight Alzheimer’s disease

biosyn Arzneimittel GmbH and AXON NEUROSCIENCE SE have long enjoyed a relationship of mutual trust during the development of Axon’s therapeutic vaccine AADvac1 to fight Alzheimer's.

Headquartered in Fellbach near Stuttgart, Germany, the family-owned pharmaceutical manufacturer is a key partner to the biotechnology company. Axon Neuroscience utilizes immunocyanin (modified KLH) manufactured by biosyn, as a carrier and immunomodulator in its vaccines.

KLH, keyhole limpet hemocyanin, is a blue-colored protein in the hemolymph of the marine mollusk Megathura crenulata and fulfils the same role as hemoglobin in human blood–transports oxygen within the body. biosyn markets the carrier molecule immunocyanin isolated from KLH under the brand name VACMUNE®.

In order to ensure the larger-scale supply of immunocyanin in the required commercial quantities and appropriate quality for the future, the two companies are delighted to announce that they have now decided to set up a joint venture company.

The primary objective of this joint venture will be to build two production facilities for the production of immunocyanin. One facility in Mexico is planned to harvest the starting material, i.e. hemolymph, extracted from keyhole limpets by an established tender, non-lethal lymph collection technique.

The facility for further purification of KLH and production of immunocyanin will be set up in Germany.

Into this venture, biosyn contributes its production know-how, bolstered by Axon Neuroscience as a strong financial partner. For decades, the German-based, family-run company has been making the carrier molecule KLH viable for use in human vaccines in compliance with the recognized standards of Current Good Manufacturing Practice (cGMP) and registered with EMA and FDA.

For many years, Axon has been developing AADvac1 vaccine, an active immunotherapy aimed at halting progression of Alzheimer's disease. The vaccine is designed to prevent neuronal protein tau from aggregating and spreading the aggregated forms throughout the brain. These abnormal tau aggregates gradually damage neurons, which leads to their death. Such deposits are a hallmark of Alzheimer's disease and other neurodegenerative diseases. The trial results obtained thus far on AADvac1 have shown promising results. In a recently published study in Nature Aging on the phase II trial results, the vaccine showed an excellent safety profile and statistically significant reduction and slow-down of neurodegenerative processes and clinical outcomes.

Axon is now planning to confirm the findings in further clinical trials. And this is where the envisaged joint venture with biosyn comes into play: ensuring a long-term supply of the carrier molecule for the potential vaccine once marketing authorization has been granted and the product launched, and to ensure sufficient supply to Alzheimer’s patients.

Axon Neuroscience

AXON NEUROSCIENCE SE was founded in 1999 by the immunologist, Professor Michal Novak. In 1988, while working at the Laboratory of Molecular Biology, MRC in Cambridge, UK, Professor Novak co-discovered tau protein to be the major cause of neurofibrillary tangles (NFTs) in Alzheimer's disease.

Currently, Axon has the single biggest team in the world dedicated exclusively to tau research, employing over 60 scientists and 15 senior scientists. Over the last two decades, Axon has published a large body of evidence demonstrating that pathological tau is the main driver of Alzheimer's disease.

Internet address of Axon Neuroscience:

Media Contact at Axon Neuroscience:

George Salapa

+421 910 571 065

  1. Axon
  2. Alzheimer
  3. KLH